INNOCARE PHARMA LTD risk profile
31 Normal where most of the sector sits
Measured 16 September 2026 from 33C's filed statements. Recomputed nightly.
31 (Normal), driven by Cash conversion at 72, over 4 weighted categories on the GENERAL profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 50 | Elevated | Stable | Drawdown from the 52-week high — 21.6% |
| Operating pressure | 0 | Contained | Easing | Costs outgrowing revenue — -112.9 percentage points |
| Cash conversion | 72 | Stretched | Easing | Cash conversion — 0.13x |
| Leverage and coverage | 4 | Contained | Easing | Interest cover — 15.30x |
| Competitive position | Reads research_and_development, operating_income, revenue, peer cohort and disclosed transition KPIs. No reading is stored for this company. | |||
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Financials, valuation and price history for INNOCARE PHARMA LTD